For the quarter ending 2026-03-31, NXTC had -$10,815K decrease in cash & cash equivalents over the period.
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Net loss | -9,796 | -9,436 | -8,624 | -37,784 |
| Depreciation and amortization | 283 | 365 | 533 | 1,287 |
| Amortization of premiums and discounts on marketable securities | 59 | 49 | 46 | 386 |
| Stock-based compensation | 344 | 435 | 600 | 1,951 |
| Noncash operating lease expense | 154 | 151 | 148 | 288 |
| Prepaid expenses and other assets | 308 | -1,623 | -1,195 | 1,716 |
| Accounts payable | 1,059 | -380 | -153 | -2,809 |
| Accrued liabilities and other liabilities | 4,735 | 49 | -367 | -4,016 |
| Lease liabilities | -269 | -263 | -254 | -488 |
| Other long-term liabilities | -36 | -35 | -34 | -66 |
| Net cash used in operating activities | -13,363 | -7,638 | -6,268 | -35,707 |
| Sales and maturities of marketable securities | 1,300 | 6,003 | 8,700 | 37,558 |
| Purchases of marketable securities | - | 0 | 0 | 26,705 |
| Net cash provided by investing activities | 1,300 | 6,003 | 8,700 | 10,853 |
| Proceeds from issuance of common stock | - | 20,276 | 0 | 2,000 |
| Net proceeds from at-the-market sales | 1,234 | - | - | - |
| Proceeds from shares issued under espp | - | 17 | 0 | 19 |
| Proceeds from exercise of stock options | 14 | - | - | - |
| Net cash provided by financing activities | 1,248 | 20,293 | 0 | 2,019 |
| Net increase (decrease) in cash and cash equivalents | -10,815 | 18,658 | 2,432 | -22,835 |
| Cash and cash equivalents - beginning of period | 25,982 | 7,324 | 27,727 | - |
| Cash and cash equivalents - end of period | 15,167 | 25,982 | 7,324 | - |
NextCure, Inc. (NXTC)
NextCure, Inc. (NXTC)